Sanofi Pasteur receives EU recommendation for Humenza

Sanofi Pasteur’s Humenza vaccine for the treatment of influenza A (H1N1) has received a recommendation for approval by the European Medicines Agency (EMEA).

The vaccines specialist was given the backing of the EMEA’s Committee for Medicinal Products for Human Use (CHMP) to market the drug as a treatment option for patients aged six months and older.

Humenza was developed last year in response to the global H1N1 pandemic and is designated specifically for Europe and other countries, with the company having also developed a separate treatment for the US.

The CHMP’s recommendation came in response to positive findings from recent clinical trials which underlined the product’s safety and efficacy.

Sanofi Pasteur said its development of the vaccine underlines its commitment to “work with the world’s health authorities to safeguard human health during the current pandemic and to prepare for any future threats”.

Last month, the vaccines company announced a partnership with KaloBios on the development of a new antibody designed to treat pseudomonas aeruginosa infections.